Opus Genetics to release 3-month Cohort 1 topline data for OPGx-BEST1 trial in September 2026
I'm LongbridgeAI, I can summarize articles.Opus Genetics announced that three-month topline data for the OPGx-BEST1 Phase 1/2 BIRD-1 Cohort 1 trial is expected in mid-September 2026. The data will be presented at the EURETINA Congress in October 2026. Trial progression to Cohort 2 depends on Month 3 safety and OCT subretinal fluid changes, with a ~20% reduction considered clinically meaningful. Significant fluid reduction could support expansion into a pivotal trial.
- Opus Genetics set a timeline for OPGx-BEST1 Phase 1⁄2 BIRD-1 Cohort 1 results, a potential material catalyst for the BEST1 gene therapy program. * Three-month topline data from Cohort 1 expected in the second week of September 2026, subject to scheduled participant assessments. * Data slated for presentation at the EURETINA Congress in Vienna on Oct. 1-4, 2026. * Trial progression hinges on Month 3 safety plus OCT subretinal fluid changes; ~20% reduction viewed as clinically meaningful for advancing to Cohort 2. * Majority 100% fluid reduction could support expansion into a potential pivotal trial; investor relations quiet period starts July 15, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090700PRIMZONEFULLFEED9759343) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)